Blood Res.  2013 Dec;48(4):300-303. 10.5045/br.2013.48.4.300.

Lymphoplasmacytic non-Hodgkin lymphoma/Waldenstrom's macroglobulinemia with CD5+, CD23+, and CD10-

  • 1Laboratorio di Chimica-Clinica, Ematologia e Microbiologia (Ematologia/Coagulazione), Azienda Ospedaliera "S. Antonio Abate" di Gallarate, Varese, Italy.
  • 2Anatomia Patologica, Azienda Ospedaliera "S. Antonio Abate" di Gallarate, Varese, Italy.


No abstract available.

MeSH Terms

Waldenstrom Macroglobulinemia*


  • Fig. 1 Bone marrow aspirate. Lymphocytes with lymphoplasmacytoid appearance (arrows).

  • Fig. 2 (A) Bone marrow flow cytometry finding of CD5+ lymphoplasmacytic lymphoma/WM. (B) Immunohistochemistry of bone marrow biopsy showing CD5+.

  • Fig. 3 (A) Bone marrow flow cytometry finding of CD23+ lymphoplasmacytic lymphoma/WM. (B) Immunohistochemistry of bone marrow biopsy showing CD23+.


1. Waldenstrom J. Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med Scand. 1944; 117:216–247.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30:110–115. PMID: 12720118.
3. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006; 17:1275–1282. PMID: 16788002.
4. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001; 116:543–549. PMID: 11601139.
5. Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013; 121:4434–4436. PMID: 23723443.
6. Pangalis GA, Kyrtsonis MC, Kontopidou FN, et al. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Semin Oncol. 2003; 30:201–205. PMID: 12720136.
7. Naderi N, Yang DT. Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Arch Pathol Lab Med. 2013; 137:580–585. PMID: 23544948.
8. Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005; 124:414–420. PMID: 16191510.
9. Owen RG, Barrans SL, Richards SJ, et al. Waldenstrom macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001; 116:420–428. PMID: 11554171.
10. Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod Pathol. 2009; 22:807–816. PMID: 19287458.
11. Hunter ZR, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005; 5:246–249. PMID: 15794857.
12. San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003; 30:187–195. PMID: 12720134.
13. Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma. 2005; 5:278–281. PMID: 15794865.
Full Text Links
  • BR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: